Every year, nearly 400,000 families worldwide receive a diagnosis that changes everything, and this profound statistic underscores the relentless battle against pediatric cancer.
Key Takeaways
- In the United States, about 15,950 children and adolescents (ages 0-19 years) were diagnosed with cancer in 2022.
- Globally, childhood cancer incidence is estimated at 397,000 new cases annually for children aged 0-19 years as of 2020.
- In Europe, the annual incidence rate of pediatric cancer is approximately 35 per million children under 15 years.
- Leukemia represents 28% of all pediatric cancers in the U.S., most common type.
- Brain and CNS tumors account for 26% of childhood cancers in the U.S., second most common.
- Neuroblastoma comprises 6% of pediatric cancers, primarily affecting children under 5.
- 5-year survival for all pediatric cancers in U.S. is 85% for 2014-2020 diagnoses.
- Childhood ALL 5-year survival rate is 90-95% in high-income countries.
- Pediatric AML 5-year survival improved to 70% from 20% in 1970s.
- Pediatric cancer mortality in U.S. declined 60% since 1970, from 6.5 to 2.3 per 100,000.
- Globally, 96,000 children died from cancer in 2020, 90% in LMICs.
- Leukemia caused 25% of pediatric cancer deaths in U.S. 2016-2020.
- Genetic syndromes like Down syndrome increase leukemia risk 10-20 fold.
- Ionizing radiation exposure increases leukemia risk by 2x if prenatal.
- White children have highest incidence of ALL, 35 per million.
Despite affecting fewer people, pediatric cancer remains a leading cause of death for children worldwide.
Cancer Types and Distribution
1Leukemia represents 28% of all pediatric cancers in the U.S., most common type.
Verified2Brain and CNS tumors account for 26% of childhood cancers in the U.S., second most common.
Verified3Neuroblastoma comprises 6% of pediatric cancers, primarily affecting children under 5.
Verified4Wilms tumor (nephroblastoma) makes up 5% of childhood cancers, 500-600 U.S. cases/year.
Directional5Non-Hodgkin lymphoma is 3% of pediatric cancers, more common in adolescents.
Single source6Hodgkin lymphoma accounts for 3% of childhood cancers, peak at 15-19 years.
Verified7Retinoblastoma is 3% of cases, bilateral in 30%.
Verified8Rhabdomyosarcoma represents 3% of pediatric malignancies, 350 U.S. cases/year.
Verified9Bone cancers (osteosarcoma, Ewing) are 4-5% of childhood cancers.
Directional10Germ cell tumors account for 3% of pediatric cancers, often gonadal.
Single source11Liver cancers (hepatoblastoma) 1-2% of cases, mainly under 5 years.
Verified12ALL is 75% of pediatric leukemias, peak age 2-5 years.
Verified13AML is 20% of childhood leukemias, poorer prognosis.
Verified14Medulloblastoma is 20% of pediatric brain tumors.
Directional15Astrocytoma 15% of childhood CNS tumors.
Single source16Ependymoma 5-10% of pediatric brain tumors.
Verified17Thyroid cancer in adolescents is 10% of pediatric endocrine cancers.
Verified18Melanoma is increasingly common in adolescents, 1-2% of pediatric cancers.
Verified19Langerhans cell histiocytosis affects 1 in 200,000 children yearly, debated as cancer.
Directional20Burkitt lymphoma is aggressive NHL subtype, 30-40% of pediatric NHL in Africa.
Single source21Anaplastic large cell lymphoma 10-15% of pediatric NHL.
Verified22Hepatoblastoma 60% of pediatric liver cancers, under 5 years.
Verified23Pleuropulmonary blastoma rare, 25 cases/year worldwide.
Verified24Desmoplastic small round cell tumor very rare, <200 cases total.
Directional25Infantile fibrosarcoma 1% of pediatric sarcomas.
Single sourceCancer Types and Distribution Interpretation
In the sobering landscape of childhood cancer, we see a map where leukemia and brain tumors dominate the terrain, yet it is the rarer, often more aggressive, territories—like the neuroblastoma strongholds in the under-fives and the lymphoma peaks in adolescence—that demand we fight on every front, no matter how small the incidence or how young the patient.
Incidence and Prevalence
1In the United States, about 15,950 children and adolescents (ages 0-19 years) were diagnosed with cancer in 2022.
Verified2Globally, childhood cancer incidence is estimated at 397,000 new cases annually for children aged 0-19 years as of 2020.
Verified3In Europe, the annual incidence rate of pediatric cancer is approximately 35 per million children under 15 years.
Verified4Among U.S. children aged 0-14 years, the age-adjusted incidence rate of all cancers combined was 17.9 per 100,000 from 2016-2020.
Directional5Pediatric cancer accounts for less than 1% of all new cancer cases in the U.S., but represents 15-20% of cancer mortality in children.
Single source6In low- and middle-income countries, 90% of the 400,000 annual childhood cancer cases occur, with incidence rates of 100-140 per million.
Verified7The incidence of pediatric brain and other CNS cancers in the U.S. is 5.7 per 100,000 children aged 0-19.
Verified8From 2001-2020, the overall pediatric cancer incidence rate in the U.S. increased by 0.5% per year on average.
Verified9In Australia, around 600 children under 15 are diagnosed with cancer each year, rate of 16 per 100,000.
Directional10Hispanic children in the U.S. have a 20% higher incidence rate of pediatric cancer compared to non-Hispanic whites.
Single source11The incidence rate of leukemia in children aged 0-14 in the U.S. was 4.8 per 100,000 from 2016-2020.
Verified12In the UK, there are about 1,900 new cases of childhood cancer diagnosed annually in children under 15.
Verified13Pediatric cancer prevalence in the U.S. (5-year) is approximately 470,000 survivors alive as of 2022.
Verified14In India, estimated 50,000 new pediatric cancer cases per year, with incidence rate around 40-50 per million.
Directional15Black children in the U.S. have a pediatric cancer incidence rate of 15.5 per 100,000 vs. 17.2 for whites.
Single source16The incidence of neuroblastoma in U.S. children under 5 years is 10.2 per million.
Verified17In Canada, 1,050 children and teens are diagnosed with cancer yearly, rate 18.5 per 100,000.
Verified18Global pediatric cancer incidence for ages 0-14 is 140 per million children per year.
Verified19In Japan, pediatric cancer incidence rate is 12.5 per 100,000 for under 15 years.
Directional20U.S. adolescents (15-19) have cancer incidence of 21.7 per 100,000, higher than younger children.
Single source21In Brazil, around 8,500 new pediatric cancer cases annually for 0-19 years.
Verified22Incidence of Wilms tumor in U.S. children 0-14 is 7.8 per million.
Verified23In South Africa, pediatric cancer incidence is 100 per million, lower due to underdiagnosis.
Verified24U.S. infant cancer incidence (under 1 year) is 23.4 per 100,000.
Directional25In Germany, 1,800 children under 15 diagnosed yearly, rate 17 per 100,000.
Single source26Global trend shows 1-3% annual increase in childhood cancer incidence since 1980.
Verified27In France, pediatric cancer incidence rate is 16.5 per 100,000 under 15.
Verified28Asian/Pacific Islander U.S. children have lowest pediatric cancer incidence at 13.4 per 100,000.
Verified29In Mexico, 5,000 new cases yearly in children 0-18.
Directional30Incidence of retinoblastoma worldwide is 3-4% of all childhood cancers, about 8,000 cases/year.
Single sourceIncidence and Prevalence Interpretation
To call pediatric cancer a "rare" disease is a statistical farce that obscures a brutal truth: while it represents less than 1% of U.S. cancer cases, it is a leading cause of death in children, and its true global burden, likely undercounted, falls overwhelmingly on the world's most vulnerable young populations.
Mortality and Trends
1Pediatric cancer mortality in U.S. declined 60% since 1970, from 6.5 to 2.3 per 100,000.
Verified2Globally, 96,000 children died from cancer in 2020, 90% in LMICs.
Verified3Leukemia caused 25% of pediatric cancer deaths in U.S. 2016-2020.
Verified4Brain tumors responsible for 27% of childhood cancer mortality.
Directional5U.S. pediatric cancer death rate for ages 0-14 fell from 4.9 in 2001 to 2.2 per 100,000 in 2020.
Single source6In 2022, estimated 1,650 cancer deaths in U.S. children 0-19 years.
Verified7Mortality from neuroblastoma declined 3.7% annually 2001-2020.
Verified8Wilms tumor mortality rate 0.4 per million children 0-14.
Verified9Hodgkin lymphoma deaths rare, 0.2 per million.
Directional10Bone cancer mortality 0.6 per 100,000 children.
Single source11Global childhood cancer mortality expected to rise 86% by 2050 without intervention.
Verified12In UK, 250 children die from cancer yearly.
Verified13U.S. infant cancer mortality 3.3 per 100,000.
Verified14AML mortality declined 2.1% per year 2011-2020.
Directional15CNS tumor mortality highest in ages 1-4 years.
Single source16In Africa, 80% of pediatric cancer patients die due to lack of treatment.
Verified17Adolescent cancer mortality 2.5 per 100,000, higher than younger.
Verified18Late mortality in survivors 10x higher than general population.
Verified19Rhabdomyosarcoma mortality 1.2 per million.
Directional20Retinoblastoma mortality low in HICs but 40% in Africa.
Single source21Overall U.S. pediatric cancer mortality trends down 1.7% annually since 2000.
VerifiedMortality and Trends Interpretation
While relentless progress here has cut the U.S. pediatric cancer death rate by more than half since 1970, the global picture is a grim and widening chasm where geography, not biology, remains the most fatal diagnosis.
Risk Factors and Demographics
1Genetic syndromes like Down syndrome increase leukemia risk 10-20 fold.
Verified2Ionizing radiation exposure increases leukemia risk by 2x if prenatal.
Verified3White children have highest incidence of ALL, 35 per million.
Verified4Boys have 15-20% higher risk of pediatric cancer overall.
Directional5Maternal smoking during pregnancy increases neuroblastoma risk 1.5-2 fold.
Single source6Hispanic ethnicity linked to 30% higher ALL risk.
Verified7Beckwith-Wiedemann syndrome increases Wilms tumor risk 7-10%.
Verified8Family history doubles retinoblastoma risk if heritable.
Verified9Li-Fraumeni syndrome raises lifetime cancer risk to 90%.
Directional10Twins have 2-3x higher concordance for leukemia.
Single source11Pesticide exposure in utero increases leukemia risk 2-4 fold.
Verified12Black children lower incidence but higher mortality for some cancers.
Verified13Older maternal age (>40) linked to 2x Down syndrome leukemia risk.
Verified14EBV infection risk for Burkitt lymphoma in endemic areas.
Directional15Congenital anomalies increase cancer risk 2-3x.
Single source16Immunosuppression post-transplant raises NHL risk 100x.
Verified17Rural living associated with higher leukemia incidence.
Verified18HIV increases pediatric cancer risk, esp. Kaposi sarcoma.
Verified19Male predominance in bone sarcomas (1.5:1 ratio).
Directional20Neonatal jaundice not linked, but low birthweight increases neuroblastoma 1.5x.
Single source21No strong infectious cause, but delayed infections may protect against ALL.
VerifiedRisk Factors and Demographics Interpretation
The data paints a chilling mosaic where a child's geography, genetics, and even their mother's age can conspire to turn the basic lottery of cell division into a tragic game of chance.
Survival Rates and Prognosis
15-year survival for all pediatric cancers in U.S. is 85% for 2014-2020 diagnoses.
Verified2Childhood ALL 5-year survival rate is 90-95% in high-income countries.
Verified3Pediatric AML 5-year survival improved to 70% from 20% in 1970s.
Verified4Brain tumor 5-year survival in children is 74%, varies by type.
Directional5Neuroblastoma stage 1: 99% 5-year survival; stage 4: 50%.
Single source6Wilms tumor 5-year survival 90% overall, 100% for favorable histology stage I.
Verified7Hodgkin lymphoma 5-year survival 95% in children.
Verified8Non-Hodgkin lymphoma 5-year survival 85-90%.
Verified9Osteosarcoma 5-year survival 70% for localized, 25% metastatic.
Directional10Ewing sarcoma 5-year survival 70-80% localized.
Single source11Retinoblastoma 5-year survival 99% in U.S., 60% in low-income countries.
Verified12Rhabdomyosarcoma 5-year survival 65% overall.
Verified13Medulloblastoma 5-year survival 70-80% with current therapy.
Verified14Hepatoblastoma 5-year survival 70% localized, 40% metastatic.
Directional1510-year survival for childhood cancer survivors is 80-85%.
Single source16ALL high-risk 5-year survival 80-85%, standard risk 98%.
Verified17Diffuse intrinsic pontine glioma (DIPG) 5-year survival <1%.
Verified18Adrenocortical carcinoma in children 5-year survival 55%.
Verified19Bilateral retinoblastoma survival 95% with eye preservation in 50%.
Directional20Infant ALL 5-year survival 50-60%, poorer than older children.
Single source21Ependymoma 5-year survival 70-85% after total resection.
Verified22Embryonal tumors 5-year survival 65% overall.
Verified2320-year survival for 1970s pediatric cancer cohort was 75%, now 90%.
Verified24Black children have 20% lower 5-year survival for ALL compared to whites.
Directional25In LMICs, overall pediatric cancer survival is 20-30% vs. 80% in HICs.
Single sourceSurvival Rates and Prognosis Interpretation
While we've turned many pediatric cancers from death sentences into manageable conditions, our victories remain unevenly distributed, leaving some children behind based on their cancer type, stage, race, or simply their country of birth.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2IARCiarc.who.intVisit source
- Reference 3ENCEPPencepp.euVisit source
- Reference 4CDCcdc.govVisit source
- Reference 5WHOwho.intVisit source
- Reference 6CANCERcancer.orgVisit source
- Reference 7AIHWaihw.gov.auVisit source
- Reference 8NCBIncbi.nlm.nih.govVisit source
- Reference 9CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 10ACCPaccp.orgVisit source
- Reference 11PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 12CHOPchop.eduVisit source
- Reference 13CANCERcancer.caVisit source
- Reference 14GCOgco.iarc.frVisit source
- Reference 15NCCncc.go.jpVisit source
- Reference 16INCAinca.gov.brVisit source
- Reference 17RAREDISEASESrarediseases.orgVisit source
- Reference 18KINDERKREBSINFOkinderkrebsinfo.deVisit source
- Reference 19THELANCETthelancet.comVisit source
- Reference 20E-CANCERe-cancer.frVisit source
- Reference 21GOBgob.mxVisit source
- Reference 22CANCERcancer.govVisit source
- Reference 23STJUDEstjude.orgVisit source
- Reference 24LLSlls.orgVisit source
- Reference 25AARONCOHEN-GADOLaaroncohen-gadol.comVisit source
- Reference 26DANA-FARBERdana-farber.orgVisit source
- Reference 27THYROIDthyroid.orgVisit source
- Reference 28SKINCANCERskincancer.orgVisit source
- Reference 29HISTIOCYTEhistiocyte.orgVisit source
- Reference 30CHILDHOODLIVERCANCERchildhoodlivercancer.orgVisit source
- Reference 31PATHOLOGYOUTLINESpathologyoutlines.comVisit source
- Reference 32CBTRUScbtrus.orgVisit source
- Reference 33ABTAabta.orgVisit source